These findings are supported by experimental and clinical observations over 30 years, which show that progressive nephropathies can be attenuated, but not completely blocked, by early treatment with AT1R antagonists or angiotensin-converting enzyme inhibitors (40, 47–49). This evidence concerns the gene ACE and kidney disorder.